CA2969814C - Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof - Google Patents

Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof Download PDF

Info

Publication number
CA2969814C
CA2969814C CA2969814A CA2969814A CA2969814C CA 2969814 C CA2969814 C CA 2969814C CA 2969814 A CA2969814 A CA 2969814A CA 2969814 A CA2969814 A CA 2969814A CA 2969814 C CA2969814 C CA 2969814C
Authority
CA
Canada
Prior art keywords
disease
compound
autoimmune
disorder
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2969814A
Other languages
English (en)
French (fr)
Other versions
CA2969814A1 (en
Inventor
Milton L. GREENBERG
John T. Ransom
Clayton A. WHITE
Omed S. MUZAFFERY
Andrew C. NEWMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivreon Biosciences LLC
Original Assignee
Vivreon Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivreon Biosciences LLC filed Critical Vivreon Biosciences LLC
Publication of CA2969814A1 publication Critical patent/CA2969814A1/en
Application granted granted Critical
Publication of CA2969814C publication Critical patent/CA2969814C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2969814A 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof Active CA2969814C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103033P 2015-01-13 2015-01-13
US62/103,033 2015-01-13
PCT/US2016/012909 WO2016115054A2 (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
CA2969814A1 CA2969814A1 (en) 2016-07-21
CA2969814C true CA2969814C (en) 2023-06-13

Family

ID=56406559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2969814A Active CA2969814C (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Country Status (9)

Country Link
US (1) US10213412B2 (https=)
EP (1) EP3245189B1 (https=)
JP (1) JP6764866B2 (https=)
CN (1) CN107207431B (https=)
AU (1) AU2016207014B2 (https=)
CA (1) CA2969814C (https=)
ES (1) ES2825798T3 (https=)
MX (1) MX379440B (https=)
WO (1) WO2016115054A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2825798T3 (es) 2015-01-13 2021-05-17 Vivreon Biosciences Llc Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos
US20200237743A1 (en) * 2017-10-17 2020-07-30 Rhizen Pharmaceuticals Sa Crac channel modulators for treating esophageal cancer
AU2018360367A1 (en) * 2017-10-30 2020-05-28 Rhizen Pharmaceuticals Sa Calcium release-activated calcium channel modulators for treating hematological and solid cancers
SG11202102491RA (en) 2018-09-14 2021-04-29 Rhizen Pharmaceuticals A G Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
PH12022552447A1 (en) * 2020-03-16 2024-01-03 Zomagen Biosciences Ltd Nlrp3 modulators
JP2023526505A (ja) * 2020-05-20 2023-06-21 カルシメディカ，インク． 急性腎障害を治療するための方法および組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) * 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
BR9306040A (pt) 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
ES2185693T3 (es) * 1994-01-19 2003-05-01 Sankyo Co Derivado de pirrolopiridacina.
JP3143571B2 (ja) * 1994-01-19 2001-03-07 三共株式会社 ピロロピリダジン誘導体
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
EP1896446A1 (en) * 2005-06-24 2008-03-12 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
ES2602140T3 (es) * 2011-06-27 2017-02-17 Newron Pharmaceuticals S.P.A. Derivados de arilalquilaminocarboxamida fluorados
AU2014282886A1 (en) * 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
ES2825798T3 (es) 2015-01-13 2021-05-17 Vivreon Biosciences Llc Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos

Also Published As

Publication number Publication date
HK1245797A1 (en) 2018-08-31
EP3245189A2 (en) 2017-11-22
CN107207431A (zh) 2017-09-26
WO2016115054A3 (en) 2016-09-01
EP3245189A4 (en) 2018-07-18
US10213412B2 (en) 2019-02-26
JP2018502083A (ja) 2018-01-25
CA2969814A1 (en) 2016-07-21
AU2016207014B2 (en) 2020-07-16
JP6764866B2 (ja) 2020-10-07
CN107207431B (zh) 2021-02-09
US20180263960A1 (en) 2018-09-20
EP3245189B1 (en) 2020-07-22
MX379440B (es) 2025-03-11
MX2017009164A (es) 2018-03-06
WO2016115054A2 (en) 2016-07-21
AU2016207014A1 (en) 2017-07-06
ES2825798T3 (es) 2021-05-17

Similar Documents

Publication Publication Date Title
CA2969814C (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
US20230312575A1 (en) Ligands to cereblon (crbn)
RS57493B1 (sr) Novi sastavi, upotrebe i metode za njihovo spravljanje
BR112021002327A2 (pt) derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer
US11623928B2 (en) Compositions, uses and methods for making them
JP2024517443A (ja) がんの治療に有用なモレファンチン誘導体
HK1245797B (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CA3181979A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
US12138243B2 (en) Antiviral use of FABP4 modulating compounds
CA3178187A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
EP4522624A1 (en) Compositions useful for modulating splicing
WO2023067388A1 (en) Uses of cftr modulator and/or pde4 inhibitor compounds
KR20220132538A (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
CA2941703A1 (en) Cancer stem cell targeting compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223